From: Impact of antigen avoidance test for fibrotic hypersensitivity pneumonitis in stable phase
Subjects | Positive antigen avoidance test (n = 17) | Negative antigen avoidance test (n = 23) | p-value |
---|---|---|---|
Age (years) | 73 (69–77) | 74 (67–77) | 0.94 |
Sex (M/F), n | 7/ 10 | 13/ 9 | 0.34 |
Smoking history (Yes), n | 5 | 13 | 0.12 |
Surgical lung biopsy, n | 5 | 9 | 0.74 |
Cryobiopsy, n | 13 | 17 | 1.00 |
CT performed after the antigen avoidance test, n | 15 | 18 | 0.68 |
White blood cell (/μL) | 6100 (5750–6910) | 5630 (4990–7170) | 0.71 |
C-reactive protein (mg/dL) | 0.10 (0.06–0.15) | 0.10 (0.05–0.28) | 0.06 |
Serum Krebs von den Lungen-6 (U/mL) | 1627 (821–2906) | 1637 (1015–2509) | 0.62 |
FVC (L) | 1.92 (1.62–2.49) | 2.12 (1.87–2.76) | 0.26 |
FVC %pred (%) | 80 (64–90) | 78 (67–94) | 0.91 |
PaO2 (Torr) | 78.5 (68.9–85.6) | 82.9 (75.0–91.8) | 0.89 |
A-aDO2 (Torr) | 19.0 (13.5–25.9) | 18.0 (9.1–22.5) | 0.19 |
BAL lymphocytes (%) | 43 (24–64) | 25 (17–45) | 0.27 |
Anti-bird IgG antibodies (mgA/L) | 14 (10–19) | 12 (8–14) | 0.13 |
Anti-Tricosporon asahii IgG antibody (CAI) | 0.01 (0–0.04) | 0.00 (0–0.05) | 0.48 |
Airway-centered fibrosis, n | 11 | 18 | 0.48 |
Lymphocyte-predominant bronchiolitis, n | 11 | 15 | 1.00 |
Poorly formed granulomas, n | 12 | 13 | 0.51 |
Fibroblastic foci, n | 9 | 19 | 0.08 |
Organizing pneumonia, n | 13 | 19 | 0.70 |
Prednisolone, n | 0 | 1 | |
Immunosuppressant, n | 0 | 1 | |
Anti-fibrotic agents, n | 0 | 1 |